Nation Pharmaceutical Pricing Authority (NPPA) has been on a roll - first reducing the cost of life saving drugs and then reducing the cost of stents in India. Championing the cause of affordable medicine further, NPAA has further reduced the cost life saving cancer drugs, some by as much as 85%.
The drugs include Iressa of AstraZeneca Pharma India, whose price has been bought down from Rs 29,259 to Rs 3,977, a reduction of 86 per cent and Dr Reddy's laboratories' Grafeel - the price of which has been slashed by 41 per cent, it said.
The reduction is in the price range of 86 per cent to 13 per cent, NPPA said.
The other pharma players the prices of whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.
In the diabetes segment also, there has been reduction in prices of the drugs, the regulator said.
Source (Times of India)
The drugs include Iressa of AstraZeneca Pharma India, whose price has been bought down from Rs 29,259 to Rs 3,977, a reduction of 86 per cent and Dr Reddy's laboratories' Grafeel - the price of which has been slashed by 41 per cent, it said.
The reduction is in the price range of 86 per cent to 13 per cent, NPPA said.
The other pharma players the prices of whose cancer medicines have been reduced are Natco Pharma and Emcure pharmaceuticals among others, it added.
In the diabetes segment also, there has been reduction in prices of the drugs, the regulator said.
Source (Times of India)
Comments
Post a Comment